ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity
The attached link to research conducted in 2008 demonstrated that [ONCY's] reovirus directly activates human DC and that reovirus-activated DC stimulate innate killing by not only NK cells, but also T cells, and suggested a novel potential role for T cells in oncolytic virus-induced local tumor cell death.
It has been subsequently shown that reovirus recognition by DC triggers innate effector mechanisms to complement the virus’s direct cytotoxicity, potentially enhancing the efficacy of reovirus as a therapeutic agent.
For example, data from the pancreatic cohort in the Goblet Phase 1/2 cancer study showed a correlation between the expansion of TIL-specific clones and tumor response, which provides compelling support for the use of pelareorep-based therapies in immunologically “cold” tumors. In particular, these data, along with the impressive clinical results, support the ability of pelareorep-checkpoint inhibitor combination therapies to meaningfully improve treatment responses in diseases like pancreatic cancer that have resisted immune-based therapeutic approaches.
https://journals.aai.org/jimmunol/article/180/9/6018/78455/Reovirus-Activates-Human-Dendritic-Cells-to
https://oncolyticsbiotech.com/press_releases/oncolytics-presents-positive-updated-pancreatic-cancer-data-from-goblet-phase-1-2-study-at-esmo/